Proposal for Omaveloxolone (RTA 408; Reata Pharmaceuticals)

Overview of Therapeutic Candidate:
Omaveloxolone (RTA 408) is a semisynthetic oleanane triterpenoid developed by Reata Pharmaceuticals. It belongs to the synthetic triterpenoid class that was designed via lead optimization strategies starting from naturally occurring oleanolic acid derivatives. The synthesis of omaveloxolone involved chemical modifications on the oleanane scaffold, a pentacyclic framework common to many triterpenoid natural products, to improve efficacy and pharmacological safety profiles. This class of compounds is historically known for their potent antioxidant and anti‐inflammatory activities because of their capacity to activate phase 2 cytoprotective response pathways via NRF2 activation (Creelan et al., 2017; Dinkova-Kostova, 2023). Omaveloxolone’s unique structure allows it to interact with the KEAP1 protein through a reversible covalent mechanism, a hallmark shared by synthetic triterpenoids that aim to enhance the cellular stress response. Generally, compounds in this class have been used in various preclinical studies and early-phase clinical trials for conditions characterized by oxidative stress and inflammation, such as cancer, neurodegenerative diseases, and mitochondrial disorders (Lee, 2023).

Therapeutic History:
Omaveloxolone has been extensively studied in multiple clinical contexts, most notably in Friedreich’s ataxia, where it garnered FDA approval based on its ability to improve neurological function and mitochondrial bioenergetics in affected patients. Early Phase I and II clinical studies have established its favorable safety and pharmacokinetic profiles in subjects with advanced solid tumors and mitochondrial myopathies, providing a supportive background for repurposing it for additional indications (Creelan et al., 2017; Reisman et al., 2019). Although direct clinical trials for dry age‐related macular degeneration (AMD) have not been reported, several clinical trial searches outline that omaveloxolone has been explored in ocular contexts and macular degeneration models, particularly focusing on cellular models such as ARPE-19 cells in which NRF2 activation shows promising antioxidant effects (ClinicalTrials.gov, n.d.). Additionally, omaveloxolone has been formulated for topical ocular applications in clinical trials aimed at reducing inflammation after ocular surgery (ClinicalTrials.gov, 2014a; ClinicalTrials.gov, 2014b), thereby demonstrating its versatility and acceptable ocular safety profile. Beyond human studies, while there is less evidence for veterinary applications directly, the broad therapeutic history of NRF2 activators in mitigating oxidative stress suggests potential translatable benefits in degenerative retinal diseases.

Mechanism of Action:
The primary mechanism of omaveloxolone is mediated by its action on the NRF2–KEAP1 pathway—a master regulator of antioxidant defense. Under basal conditions, NRF2 is bound to KEAP1, which facilitates its ubiquitination and proteasomal degradation. Omaveloxolone binds specifically to the cysteine residue (notably Cys151) on KEAP1; by modifying this residue, it disrupts the KEAP1-NRF2 interaction, thereby stabilizing NRF2 and allowing its nuclear translocation (Creelan et al., 2017; Dinkova-Kostova, 2023). In the nucleus, NRF2 binds to antioxidant response elements (ARE) in the promoter regions of target genes, which results in the upregulation of a battery of cytoprotective enzymes such as NAD(P)H quinone oxidoreductase 1 (NQO1), glutamate–cysteine ligase catalytic subunit (GCLC), heme oxygenase-1 (HO-1), and others. This transcriptional activation alleviates oxidative stress by enhancing the cell’s capacity to detoxify reactive oxygen and nitrogen species (Zighan et al., 2022; Creelan et al., 2017). Additionally, omaveloxolone not only reduces oxidative injury but also exerts anti-inflammatory effects, as evidenced by its capacity to decrease IL-1β release, suppress interferon-γ-mediated nitric oxide signaling in macrophages, and improve mitochondrial membrane potential (Creelan et al., 2017). These molecular interactions are particularly relevant in retinal pigment epithelium (RPE) cells, where a reduction in oxidative stress can alleviate impaired phagocytic function and lysosomal dysfunction, known contributors to dry AMD pathology (Catanzaro et al., 2020; Chen et al., 2023).

Expected Effect:
The hypothesis for repurposing omaveloxolone in dry AMD is that its NRF2 activation will enhance the antioxidant gene profile in RPE cells, which are critical for maintaining retinal health. In the proposed assays using ARPE-19 cells—a well-characterized in vitro model of RPE—the expectation is that omaveloxolone will lead to increased expression of cytoprotective genes that counteract oxidative stress, thereby reducing the priming of the inflammasome and decreasing IL-1β secretion. Such biochemical adjustments are expected to protect the mitochondrial function and maintain lysosomal pH homeostasis, which is essential for the effective phagocytosis of photoreceptor outer segments (POS) via receptors such as MerTK/αvβ5. Evidence from biochemical studies supports that NRF2 and its downstream targets are expressed in RPE cells, and their activation has been correlated with enhanced phagocytic clearance and reduced cellular senescence in models of AMD (Cai et al., 2021; Creelan et al., 2017). Moreover, preclinical studies have shown that topical ocular formulations of NRF2 activators can achieve therapeutic retinal exposure. Given that omaveloxolone has shown promise in decreasing oxidative markers and preserving mitochondrial integrity in various cell types, it is reasonable to predict that in ARPE-19 cells, similar protective effects will lead to improved POS clearance and overall RPE cell viability under oxidative conditions, which is a critical therapeutic goal in dry AMD (ClinicalTrials.gov, n.d.).

Overall Evaluation:
In summary, omaveloxolone presents a compelling therapeutic candidate for the treatment of dry AMD based on its robust mechanism of NRF2 activation, a validated target for oxidative stress reduction in RPE cells. Its synthetic triterpenoid origin and chemical optimization confer potent antioxidant and anti-inflammatory properties, which have been substantiated in preclinical and early-phase clinical studies across several indications including Friedreich’s ataxia and ocular inflammation post-surgery (Creelan et al., 2017; Lee, 2023). The strengths of omaveloxolone lie in its molecular specificity—activating the NRF2 pathway via KEAP1 binding—and its capacity to induce a cytoprotective gene expression program that addresses multiple pathophysiological processes implicated in dry AMD, including oxidative stress, inflammasome activation, mitochondrial dysfunction, and defective phagocytosis of POS. Its favorable safety profile in previous clinical trials, particularly those demonstrating minimal adverse events in systemic applications, further supports its potential for repurposing in an ocular context where dose and exposure can be finely controlled with topical formulations (Creelan et al., 2017; ClinicalTrials.gov, n.d.).

However, several challenges remain. Although omaveloxolone’s mechanism is well elucidated in non-ocular models, its specific pharmacokinetics and pharmacodynamics in the retinal environment require further investigation, particularly concerning its ability to achieve adequate retinal tissue penetration while maintaining low ocular toxicity. Additionally, while the theoretical benefits in RPE cells are clear, direct evidence from preclinical models of dry AMD and studies in relevant animal models are still limited, making it imperative to validate these effects in dedicated ocular experiments. There is also the concern of potential off-target effects or a narrow therapeutic window associated with NRF2 activators; careful dose range optimization will be necessary to balance efficacy with safety, particularly if long-term treatment is envisaged for a chronic condition like dry AMD (Clay et al., 2019; Dinkova-Kostova, 2023).

Overall, the candidate’s ability to target a key molecular pathway that is directly implicated in the pathogenesis of dry AMD makes it a strong candidate for further research. The convergence of biochemical evidence from ARPE-19 cell studies, supportive clinical safety data from related trials, and the mechanistic rationale for NRF2 activation collectively justify the continued development and repurposing of omaveloxolone for dry AMD. It is recommended that additional preclinical studies focusing on ocular pharmacokinetics, efficacy in animal models of AMD, and detailed mechanistic studies in RPE cells be undertaken to further validate this promising therapeutic avenue (Cai et al., 2021; Catanzaro et al., 2020; Creelan et al., 2017).

This detailed evaluation supports the strategic decision to move forward with omaveloxolone as a promising candidate for dry AMD, recognizing its strengths in modulating key oxidative stress pathways while also acknowledging the critical gaps that must be addressed in subsequent studies.

References:
Buonfiglio, F., Korb, C., Stoffelns, B., Pfeiffer, N., & Gericke, A. (2024). Recent advances in our understanding of age-related macular degeneration: Mitochondrial dysfunction, redox signaling, and the complement system. Aging and Disease. Advance online publication. https://doi.org/10.14336/ad.2024.0124

Cai, Z., Fu, M., Liu, K., & Duan, X. (2021). Therapeutic effect of keap1-nrf2-are pathway-related drugs on age-related eye diseases through anti-oxidative stress. International Journal of Ophthalmology, 14, 1260–1273. https://doi.org/10.18240/ijo.2021.08.19

Catanzaro, M., Lanni, C., Basagni, F., Rosini, M., Govoni, S., & Amadio, M. (2020). Eye-light on age-related macular degeneration: Targeting nrf2-pathway as a novel therapeutic strategy for retinal pigment epithelium. Frontiers in Pharmacology, 11, Article 844. https://doi.org/10.3389/fphar.2020.00844

Chen, J., Maurya, M., Bora, K., Blomfield, A. K., Pavlovich, M. C., Huang, S., & Liu, C.-H. (2023). Oxidative stress in retinal pigment epithelium degeneration: From pathogenesis to therapeutic targets in dry age-related macular degeneration. Neural Regeneration Research, 18, 2173–2181. https://doi.org/10.4103/1673-5374.369098

Clay, A., Hearle, P., Schadt, K., & Lynch, D. R. (2019). New developments in pharmacotherapy for Friedreich ataxia. Expert Opinion on Pharmacotherapy, 20, 1855–1867. https://doi.org/10.1080/14656566.2019.1639671

Creelan, B., Gabrilovich, D., Gray, J., Williams, C., Tanvetyanon, T., Haura, E., Weber, J., Gibney, G., Markowitz, J., Proksch, J., Reisman, S., McKee, M., Chin, M., Meyer, C., & Antonia, S. (2017). Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors. OncoTargets and Therapy, 10, 4239–4250. https://doi.org/10.2147/OTT.S136992

Dinkova-Kostova, A. (2023). Keap1/Nrf2 as a druggable target. Arhiv za Farmaciju, 73, 89–108. https://doi.org/10.5937/arhfarm73-43475

Edzeamey, F. J., Ramchunder, Z., Pourzand, C., & Virmouni, S. A. (2024). Emerging antioxidant therapies in Friedreich’s ataxia. Frontiers in Pharmacology. Advance online publication. https://doi.org/10.3389/fphar.2024.1359618

Lee, A. (2023). Omaveloxolone: First approval. Drugs, 83, 725–729. https://doi.org/10.1007/s40265-023-01874-9

Reisman, S. A., Gahir, S. S., Lee, C.-Y. I., Proksch, J. W., Sakamoto, M., & Ward, K. W. (2019). Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates. Drug Design, Development and Therapy, 13, 1259–1270. https://doi.org/10.2147/DDDT.S193889

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery: GUARD (ClinicalTrials.gov Identifier: NCT02128113). (2014). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02128113

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery (ClinicalTrials.gov Identifier: NCT02065375). (2014). ClinicalTrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02065375

Zighan, M., Arkadir, D., Douiev, L., Keller, G., Miller, C., & Saada, A. (2022). Variable effects of omaveloxolone (RTA408) on primary fibroblasts with mitochondrial defects. Frontiers in Molecular Biosciences, 9, Article 890653. https://doi.org/10.3389/fmolb.2022.890653
